A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Daratumumab (Primary) ; Daratumumab (Primary)
  • Indications Multiple myeloma
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 07 Sep 2017 Status changed from planning to not yet recruiting.
    • 24 May 2017 New trial record
    • 17 May 2017 According to a Gemmab media release, this study is currently planned to start between the second half of 2017 and the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top